Street View: AbbVie's next growth chapter gains analysts' confidence

** AbbVie stated on Thursday that its exposure to tariffs is unlikely to surpass that of its competitors, and it raised its 2025 earnings outlook, crediting robust sales of its newer immunology treatments, Skyrizi and Rinvoq

** Median PT of 28 brokerages covering the stock is 'buy' - LSEG data

RECHARGED, AND READY TO RUN

** J.P.Morgan ("overweight," PT: $200) sees AbbVie as a solid long-term play, driven by strong Skyrizi and Rinvoq sales, with no major patent risks until the mid-2030s

** Leerink Partners ("outperform," PT: $210) is upbeat on AbbVie, highlighting strong momentum from newer drugs that are offsetting older product declines and supported by promising clinical trial progress

** Raymond James ("outperform," PT: $236) highlights AbbVie's strong fundamentals, accelerating pipeline momentum, and a successful post-Humira transition as key drivers of long-term growth

** Morningstar (fairvalue: $184) "We think AbbVie is capable of 8% top-line growth in 2025, slightly ahead of guidance, based on the continuing strong prospects for sales of immunology drugs Skyrizi and Rinvoq as well as double-digit growth for several neuroscience drugs, including new Parkinson's therapy Vyalev"